Cannabis and prescription muscle relaxers are often used for overlapping problems. Someone with a back injury, muscle spasm, multiple sclerosis, chronic pain, or another painful condition may be prescribed a drug such as cyclobenzaprine, baclofen, tizanidine, methocarbamol, or carisoprodol while also using marijuana for pain, sleep, or relaxation. Because both treatments can make a person feel physically relaxed, combining them may seem intuitive. Pharmacologically, however, the combination is more complicated than simply producing additional muscle relaxation.
The central concern is that many muscle relaxers suppress or alter activity in the central nervous system. THC-containing cannabis can also cause drowsiness, dizziness, impaired attention, slower psychomotor performance, balance problems, and changes in blood pressure. When the effects overlap, a person may experience substantially more impairment than expected from either substance alone. Direct randomized trials examining modern medicinal cannabis products with most individual muscle relaxers are scarce, so scientists cannot provide a universal formula for how much cannabis is safe with each medication. FDA prescribing information, government cannabinoid reviews, human laboratory research, and pharmacology studies nevertheless provide enough evidence to justify caution, particularly with high-THC cannabis, large oral doses, concentrated CBD, and strongly sedating muscle relaxers.
Muscle Relaxers Are Not One Type of Drug
The term “muscle relaxer” describes medications with substantially different mechanisms. Cyclobenzaprine is structurally related to tricyclic antidepressants and acts mainly in the central nervous system to reduce skeletal-muscle spasm. Methocarbamol is described in FDA prescribing information as a central nervous system depressant whose muscle-relaxing benefit may be related largely to its sedative properties rather than a direct effect on skeletal muscle. Carisoprodol also produces significant CNS effects and is metabolized into meprobamate, a sedating compound with abuse and dependence potential. These medications are most commonly used for acute painful musculoskeletal conditions rather than neurological spasticity.
Baclofen and tizanidine occupy a somewhat different category. Baclofen is primarily used for spasticity associated with neurological disorders and acts through inhibitory GABA-B signaling. Tizanidine is an alpha-2 adrenergic agonist that reduces excitatory signaling in the spinal cord and is also used for spasticity. Both can cause substantial sleepiness, weakness, dizziness, and impaired coordination. Because these medications work differently, cannabis cannot be expected to interact identically with all of them. What they share is a tendency to interfere with alertness or motor control—the same functions that THC can impair.
Cannabis and Muscle Relaxers: Medication-Specific Safety Table
| Muscle Relaxer | Main Concern With Cannabis | Important Cannabis-Specific Issue | Relative Concern | Key Safety Considerations |
|---|---|---|---|---|
| Cyclobenzaprine (Flexeril) | Increased drowsiness, dizziness, slowed reaction time, and impaired coordination | THC can add to the medication’s CNS effects. Direct cannabis-cyclobenzaprine trials are lacking. | Moderate | Avoid assuming that feeling “relaxed” means coordination and judgment are normal. Extra caution is warranted with alcohol, opioids, benzodiazepines, sleep medications, or sedating antihistamines. |
| Baclofen | Sedation, weakness, dizziness, confusion, impaired coordination, and excessive CNS depression | A controlled Columbia University study involving marijuana users found that baclofen worsened performance on some cognitive and divided-attention tasks during cannabis exposure. | Moderate to Higher | Particularly important for people already experiencing weakness, balance problems, neurological disease, or substantial sedation. Baclofen should not be abruptly discontinued after regular use because withdrawal can be serious. |
| Tizanidine (Zanaflex) | Sedation, dizziness, low blood pressure, faintness, and impaired motor performance | Tizanidine depends strongly on CYP1A2 metabolism. Human cannabinoid research shows that very high oral CBD exposure can inhibit CYP1A2, creating a plausible—but not directly proven—mechanism for higher tizanidine exposure. | Higher with high-dose CBD or pronounced sedation | Watch particularly for excessive sleepiness, lightheadedness when standing, unusually low blood pressure, or fainting. Established CYP1A2 inhibitors can substantially increase tizanidine effects. |
| Methocarbamol (Robaxin) | Additive CNS depression, drowsiness, dizziness, and impaired driving ability | THC can produce many of the same functional impairments. There are few direct clinical studies examining the combination. | Moderate | Avoid driving or hazardous activities until the combined effects are understood. Risk can increase further when alcohol, opioids, benzodiazepines, or other sedatives are present. |
| Carisoprodol (Soma) | Stronger sedation, dizziness, impaired coordination, and potentially excessive CNS depression | Carisoprodol is converted through CYP2C19 to meprobamate. CBD can inhibit CYP2C19, although the clinical consequences of a CBD-carisoprodol interaction have not been directly established. | Higher | Carisoprodol already carries dependence, abuse, and overdose concerns. Combining it with intoxicating cannabis and additional CNS depressants deserves particular caution. |
| Metaxalone (Skelaxin) | Drowsiness, dizziness, and additive CNS depression | Direct cannabis interaction data are extremely limited. The main concern is overlapping impairment rather than a proven metabolic interaction. | Moderate | Sedation may become more pronounced with high-THC products or when other CNS depressants are used. |
| Orphenadrine | Drowsiness, dizziness, confusion, blurred vision, and anticholinergic effects | Cannabis may add to cognitive impairment, dizziness, and changes in perception. Direct combination studies are lacking. | Moderate | Older adults may be especially susceptible to confusion, falls, dry mouth, urinary problems, or excessive impairment. |
| Dantrolene | Weakness, dizziness, fatigue, and liver-related concerns | Dantrolene works directly on skeletal muscle rather than mainly through CNS depression, so the interaction profile differs from most muscle relaxers. High-dose CBD has independently been associated with liver-enzyme elevations in clinical research. | Moderate, with special liver consideration | People with liver disease or those using substantial CBD doses should make both products known to their clinician. New jaundice, dark urine, unusual fatigue, or persistent nausea warrants medical evaluation. |
How to Read the Table
“Relative concern” is not a ranking of which medication is inherently dangerous. It reflects how much the known effects of the muscle relaxer overlap with cannabis and whether there is an additional plausible metabolic interaction. Cannabis dose and composition matter considerably. A small amount of low-THC cannabis does not create the same exposure as a potent THC edible or hundreds of milligrams of oral CBD.
The table also should not be used to determine whether a prescription dose should be skipped or changed. Muscle relaxers such as baclofen can produce clinically important withdrawal when stopped abruptly, while other drugs may have their own discontinuation concerns. The most useful information for a physician or pharmacist is the specific muscle relaxer being taken, its dose and schedule, the approximate THC and CBD content of the cannabis product, how frequently it is used, and whether alcohol, opioids, benzodiazepines, sleep aids, or other sedating medications are also involved.
Why Cannabis Can Increase Sedation and Impairment
Government reviews of cannabinoids consistently identify dizziness and drowsiness among common adverse effects of THC-containing products. The National Cancer Institute’s cannabinoid summary lists dizziness, drowsiness, low blood pressure, and muscle relaxation among recognized effects, while evidence reviews of THC and THC/CBD medicines have repeatedly found increased rates of somnolence, balance problems, impaired attention, fatigue, and psychomotor impairment compared with placebo. These effects become particularly relevant when another medication is already suppressing the nervous system.
This type of interaction is usually described as pharmacodynamic: two substances produce similar effects even without changing one another’s blood concentration. A person who feels mildly sleepy after a muscle relaxer and mildly impaired after THC may become considerably more sedated when the two are combined. Coordination and judgment may deteriorate before the person recognizes how impaired they are. This creates practical risks involving falls, driving, machinery, stairs, and nighttime movement—especially in older adults or patients whose muscle weakness or spasticity already affects balance.
Cannabis and Cyclobenzaprine
Cyclobenzaprine is one of the most commonly prescribed medications for acute muscle spasm. Current FDA labeling warns that it can enhance the effects of alcohol and other central nervous system depressants and can impair the mental or physical abilities required for driving or operating machinery. Drowsiness is among its characteristic adverse effects. Cyclobenzaprine is also structurally related to tricyclic antidepressants and has additional anticholinergic and serotonergic properties that distinguish it from many other muscle relaxers.
No high-quality clinical trial has established exactly how much marijuana changes cyclobenzaprine impairment. The most defensible concern is therefore additive sedation rather than a proven toxic interaction. Someone taking cyclobenzaprine who adds a high-THC edible could experience greater sleepiness, dizziness, slowed reaction time, confusion, or impaired coordination. The problem may become greater if alcohol, opioids, benzodiazepines, sedating antihistamines, sleep medications, or other CNS depressants are added to the combination.
Cannabis and Baclofen
Baclofen deserves particular attention because sedation can be substantial even without cannabis. FDA prescribing information reports transient drowsiness in 10 to 63 percent of patients; in one controlled trial involving 175 people, drowsiness occurred in 63 percent of baclofen patients compared with 36 percent receiving placebo. Dizziness, weakness, fatigue, coordination problems, hypotension, and confusion are also reported. The label specifically warns that baclofen’s central nervous system effects may be additive with alcohol and other CNS depressants.
There is some direct human research involving baclofen and marijuana. Investigators at the New York State Psychiatric Institute and Columbia University tested baclofen in 10 heavy daily marijuana smokers using a controlled laboratory model. Participants received 60 or 90 milligrams of baclofen per day during periods that included active marijuana use and abstinence. Baclofen did not emerge as a useful cannabis-dependence treatment, and importantly, it worsened cognitive performance on several tasks. During active marijuana administration, the 90-milligram baclofen condition significantly reduced accuracy on a divided-attention tracking task. The study was small and was not designed to establish the safety of prescribed baclofen with recreational cannabis, but it provides unusually direct evidence that meaningful cognitive impairment can occur in people exposed to both.
Cannabis and Tizanidine
Tizanidine commonly causes sedation and can also lower blood pressure. FDA labeling warns that its sedative effects with other CNS depressants may be additive and instructs clinicians to monitor for excessive sedation. It can also produce hypotension, dizziness, and occasionally fainting. Cannabis—particularly THC—can independently cause dizziness and changes in blood pressure, meaning the combination may be especially troublesome for people prone to lightheadedness when standing.
There is also a possible metabolic issue, although clinical evidence is limited. Tizanidine is highly dependent on CYP1A2 for metabolism. A 2023 human study performed by researchers from the University of Washington and Johns Hopkins University found that a high-dose CBD-dominant cannabis extract containing 640 milligrams of CBD plus 20 milligrams of THC inhibited CYP1A2, increasing exposure to the CYP1A2 probe caffeine by approximately 39 percent. The THC-only preparation did not produce the same interaction. This does not prove that ordinary CBD use will significantly increase tizanidine concentrations, and no direct tizanidine-CBD trial has established the magnitude of such an effect. It does demonstrate that sufficiently high oral CBD exposure can inhibit the same pathway used to eliminate tizanidine.
Cannabis and Methocarbamol
Methocarbamol is explicitly classified in prescribing information as a CNS depressant with sedative and musculoskeletal-relaxant properties. Its exact mechanism in humans has not been fully established, but the FDA label notes that its clinical effect may relate to general central nervous system depression rather than direct relaxation of skeletal muscle. Drowsiness and dizziness are recognized effects, and patients are warned that methocarbamol can impair driving and other hazardous activities. The label also cautions that its effects may combine with alcohol and other CNS depressants.
These characteristics make a cannabis-methocarbamol combination primarily an impairment concern. There is little direct clinical research specifically comparing methocarbamol alone with methocarbamol plus THC, so claims that the combination is inherently dangerous—or inherently safe—go beyond the available evidence. Still, a person using THC at the same time may experience increased dizziness, drowsiness, slowed thinking, or balance problems. Since methocarbamol is often prescribed after injuries involving the back or other musculoskeletal structures, additional impairment may be particularly undesirable during recovery.
Cannabis and Carisoprodol
Carisoprodol may represent one of the more concerning muscle relaxers to combine with intoxicating cannabis because sedation is prominent and the medication itself has recognized misuse and dependence potential. FDA labeling reports sedation in approximately 13 to 17 percent of patients in low-back-pain trials compared with about 6 percent receiving placebo. Drowsiness, dizziness, vertigo, ataxia, fainting, and seizures have also been reported, and postmarketing reports have linked the medication with motor-vehicle accidents. Its label specifically warns that sedative effects can be additive with other CNS depressants.
Carisoprodol is converted by CYP2C19 into meprobamate, another sedating drug. CBD is a clinically demonstrated inhibitor of CYP2C19 at sufficiently high doses. In the University of Washington/Johns Hopkins cannabinoid interaction trial, the CBD-dominant preparation increased exposure to omeprazole, the study’s CYP2C19 probe, by approximately 207 percent. It is not possible to translate that result directly into a prediction for carisoprodol, because parent carisoprodol and meprobamate contribute differently to the drug’s clinical effects. The finding nonetheless reinforces why concentrated oral CBD should not be assumed to be interaction-free simply because it does not produce a marijuana high.
THC and CBD Create Different Interaction Problems
THC is usually the more immediate concern for functional impairment. It can produce intoxication, dizziness, drowsiness, slowed reaction time, altered perception, and impaired coordination. Higher doses—particularly edibles and concentrates—can produce stronger and longer-lasting effects than a person expects. Combining those effects with a sedating muscle relaxer may make driving or other tasks significantly less safe even when neither drug is being misused.
CBD typically causes much less intoxication, but high doses can interfere with medication metabolism. The 2023 controlled interaction study in 18 healthy adults found that 640 milligrams of CBD combined with 20 milligrams of THC inhibited CYP2C19, CYP2C9, CYP3A, and CYP1A2. By contrast, 20 milligrams of THC without CBD did not meaningfully inhibit the tested enzymes. Another Johns Hopkins randomized trial using these same cannabinoid doses found that the CBD-rich formulation produced greater sedation and greater cognitive and psychomotor impairment than THC alone, partly because CBD increased systemic exposure to THC. These doses are much larger than the CBD content of many cannabis products, but they demonstrate why high-dose CBD preparations deserve separate consideration.
Driving, Falls, and Other Real-World Risks
One of the clearest reasons to avoid casually combining THC and muscle relaxers is impairment rather than a rare biochemical toxicity. Cannabis can affect attention, balance, reaction time, judgment, and coordination, while many muscle relaxers carry explicit warnings against driving until the patient understands how the medication affects them. A person may feel relaxed rather than obviously intoxicated while still performing poorly on divided-attention or coordination tasks.
Falls deserve particular attention in older adults, people recovering from orthopedic injuries, and anyone with neurological spasticity. Tizanidine and baclofen can cause weakness or hypotension, while THC can add dizziness and altered perception. Someone who uses cannabis primarily at bedtime should also remember that an oral edible may remain active for many hours, potentially overlapping with nighttime or early-morning doses of a muscle relaxer.
Respiratory Depression and Excessive CNS Depression
Cannabis by itself is not generally associated with the profound respiratory suppression characteristic of opioid overdose. That does not mean every combination with a sedating prescription drug is benign. Baclofen overdose can cause coma and respiratory depression, and carisoprodol toxicity can produce severe CNS depression. The risk becomes substantially more concerning when opioids, benzodiazepines, alcohol, sleep medications, or other depressants are added to the mixture.
Warning signs of excessive CNS depression include unusual difficulty staying awake, severe confusion, inability to walk normally, repeated falls, very slow or abnormal breathing, fainting, or inability to awaken normally. These symptoms warrant urgent medical attention. People with sleep apnea, chronic lung disease, significant kidney or liver impairment, or multiple sedating prescriptions may have less physiological margin for additional impairment.
Final Thoughts on Cannabis and Muscle Relaxers
Research does not support a universal statement that cannabis can never be used by someone taking a muscle relaxer. It also does not support treating the combination as automatically harmless. The strongest evidence points toward additive central nervous system impairment: cannabis can cause dizziness, drowsiness, balance problems, and psychomotor impairment, while cyclobenzaprine, baclofen, tizanidine, methocarbamol, and carisoprodol all have their own sedating effects. A Columbia University human laboratory study involving baclofen and marijuana additionally demonstrated measurable worsening of cognitive task performance, providing some direct evidence that these overlapping effects can matter in people.
The individual medication makes an important difference. Tizanidine adds hypotension risk; baclofen can produce substantial drowsiness and should not be stopped abruptly; carisoprodol has additional dependence and abuse concerns; methocarbamol acts largely through CNS depression; and cyclobenzaprine has tricyclic-like and serotonergic properties. High-dose CBD creates a second issue because it can inhibit multiple liver enzymes and potentially alter concentrations of certain medications. Anyone regularly combining cannabis with a prescription muscle relaxer should make the cannabis product, THC and CBD content, dose, and frequency known to the prescribing clinician or pharmacist. The safest approach is to avoid assuming that tolerance to either cannabis or the muscle relaxer guarantees tolerance to the two together—especially when driving, alcohol, opioids, benzodiazepines, or other sedating drugs are involved.
